Healthcare / Medical Instruments & SuppliesNasdaqCM
$2.44
+0.20 (+8.93%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-2.3M · quality 41.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$19M
P/E
12.2x
↓EV/EBITDA
31.9x
↑ROE
4.0%
↑Gross Margin
29.2%
↓Debt/Equity
0.64
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.5%
FCF CAGR
—
FCF margin
-18.0%
FCF / Net income
-3.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $20.7M · net income $1.2M · FCF $-3.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $20.7M | $20.7M | $23.5M | $19.8M | $19.2M |
| Net Income | $1.2M | $1.2M | $3.7M | $2.9M | $2.7M |
| EBITDA | $958861.00 | $958861.00 | $4.0M | $3.1M | $2.5M |
| EPS | — | — | 0.40 | 0.40 | 0.36 |
| Gross Margin | 29.2% | 29.2% | 40.4% | 34.2% | 32.3% |
| Operating Margin | 2.9% | 2.9% | 15.5% | 14.5% | 11.1% |
| Net Margin | 5.8% | 5.8% | 15.6% | 14.5% | 14.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.64 | 0.64 | 0.40 | 0.17 | — |
| Current Ratio | 1.85 | 1.85 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.7M | $-3.7M | $-2.3M | $3.0M | $1.5M |
| Returns | |||||
| ROE | 4.0% | 4.0% | 12.8% | 12.0% | 17.8% |
| Valuation | |||||
| P/E | 12.20 | 12.20 | 125.50 | 34.43 | — |
| EV/EBITDA | 31.86 | 31.86 | 99.43 | 31.40 | — |
| P/B | 0.64 | 0.64 | 13.63 | 4.17 | — |
| Growth & Yield | |||||
| Revenue Growth | -12.0% | -12.0% | 18.6% | 3.3% | — |
| EPS Growth | — | — | 0.0% | 10.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-83.8%
Start / end P/E
n/dx → n/dx
EPS bridge
0.40 → n/d
Residual
-83.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.